Delving into the Latest Updates on Protalex, Inc. with Synapse

Overview

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.

Start Date01 Nov 2015

Sponsor / Collaborator

Protalex, Inc.

NCT02401061

/ TerminatedPhase 1/2

A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.
Funding Source - FDA OOPD (1R01FD005750-01A1)

Start Date01 Sep 2015

Sponsor / Collaborator

Protalex, Inc.

NCT02330445

/ CompletedPhase 1/2

Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers

Part A Primary Objective To determine the safety of six months of PRTX-100 administration. Part B Primary Objective To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies.
Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100 treatment To evaluate the development of anti-PRTX-100 antibodies To explore feasibility of joint evaluations with ultrasound To explore feasibility of biomarkers as disease markers

Start Date01 Feb 2015

Sponsor / Collaborator

Protalex, Inc.

100 Clinical Results associated with Protalex, Inc.

Login to view more data

0 Patents (Medical) associated with Protalex, Inc.

Login to view more data

3

Literatures (Medical) associated with Protalex, Inc.

01 Nov 2018·British journal of haematology

A highly purified form of staphylococcal protein A alleviates murine immune thrombocytopenia (ITP)

Letter

Author: Aslam, Rukhsana ; Semple, John W ; Kapur, Rick ; Speck, Edwin R ; Francovitch, Richard F ; Catalina, Michelle D

01 Oct 2002·Cancer biotherapy & radiopharmaceuticalsQ4 · MEDICINE

Mitogen Information Summaries

Q4 · MEDICINE

Review

Author: Mann, Paul L. ; Wimer, Bruce M.

A review.Phytohemagglutinin (PHA), Con A (Con A), and pokeweed mitogen (PWM) have been key laboratory mitogens for many years during which their clin. applications have failed to evolve at an acceptable rate.PHA, the first mitogen identified, has been the one whose therapeutic potential has been most widely studied and ultimately the only one applied in humans.Con A intensely investigated by Morris showed clin. promise until unique lethal reactions in dogs have restricted its use to the laboratoryPWM has captured the limelight because of its high potency and its successful albeit inadequately exploited applications for malignancies in dogs and cats.PHA-fraction IV developed by Goldberg's group shows promise as a nonagglutinating alternative to PHA.The salient features of these four compounds are reviewed here emphasizing their generally unrecognized curative potential when given either alone or in conjunction with other therapeutic agents.Highly sophisticated products now advanced to market commonly exhibit limitations of various types that might be overcome by the enhancing effects of mitogens.

Energy Technology

The reemergence of medium scale gasification technology

Author: Reindl, Wilhelm J.

A review with no references

1

News (Medical) associated with Protalex, Inc.

13 Jun 2014

·www.biospace.com

Protalex, Inc. Announces Data from U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients Presented At The 2014 EULAR Annual European Congress of Rheumatology

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR’s Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR’s website at and the complete poster is available on the Company’s website at Help employers find you! Check out all the jobs and post your resume.

100 Deals associated with Protalex, Inc.

Login to view more data

100 Translational Medicine associated with Protalex, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data